Arthritis Rheumatol. 2022;74:1943–58
In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.
In addition, bimekizumab delivered sustained, long-term efficacy in patients with AS, including reduced disease activity and improved patient function and quality of life. Overall, these results support bimekizumab as a promising potential treatment option in AS.